BIIB— Biogen Inc.

NasdaqGS

Healthcare · Drug Manufacturers - General

$205.99-1.40%

Mkt Cap: $30.41B

Biogen Inc. (BIIB) stock trades at $205.99, down 1.40% on the day. With a market capitalization of $30.41 billion, BIIB is a large-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 22.5, a forward P/E of 12.5 and earnings per share (EPS) of $9.17. Over the most recent period the company reported 2% year-over-year revenue growth and a net profit margin of 13.8%. Below you'll find BIIB's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.

Price & Performance

Performance

Analysis & Verdict

Biogen Inc. (BIIB) Stock Analysis 2026

Rule-based · Updated daily · Not financial advice

Biogen Inc. (BIIB) operates in the Drug Manufacturers - General space within the Healthcare sector. With a market cap of $30.4B, it qualifies as a mid-cap company. Growth is moderate and the business remains profitable, offering a balanced risk/reward profile compared to high-multiple peers.

Bull Case5

Forward P/E (12.5×) is lower than trailing P/E (22.5×) — analysts expect earnings to improve
Earnings grew 31% YoY — bottom-line is expanding fast
Healthy profit margin of 13.8%
Current ratio of 3.1× — ample short-term liquidity
Low beta of 0.16 — less volatile than the market, suitable for conservative portfolios

Bear Case3

High debt-to-equity of 35.18× increases financial risk, especially with elevated interest rates
No dividend history — total return depends entirely on price appreciation
Price is near its 52-week high — limited near-term upside, higher pullback risk

Verdict

Buy / Hold

More positives than negatives. Fundamentals support holding while monitoring key risks.

AI Insight

AI-generated analysis for informational purposes only. Not financial advice.

Fair Value Estimates

Current price: $205.99

Graham Number

√(22.5 × EPS × Book Value)

$161.47

-21.6% downside

Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.

Bazin Ceiling Price

Avg. Annual DPS (5Y) ÷ 6%

N/A

Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.

These are simplified estimates. Not financial advice.

Buy & Hold Checklist

Quality criteria for long-term holding

5/10

63% score

Pays dividends

No dividend history found

Dividend consistency (5Y+)

Uninterrupted dividend payments for at least 5 years

ROE above 10%

7.7%

Return on equity — measures how efficiently capital is used

Positive profit margin

13.8%

Net profit margin must be positive — company earns more than it spends

Revenue growth (annual)

+1.9%

Annual revenue must be growing compared to the prior year

Earnings growth (annual)

+31.1%

Annual earnings must be growing compared to the prior year

Debt/Equity below 2×

35.18×

Low financial leverage reduces risk of distress

Current ratio above 1

3.06×

Short-term assets must cover short-term liabilities

Daily liquidity above $5M

$262M/day

High trading volume ensures easy entry and exit

Dividend yield above 0%

Stock must distribute income to shareholders

Financials

Revenue & Results

Key Statistics

Market Cap$30.41B

P/E Ratio22.46

Forward P/E12.45

P/B Ratio—

PEG Ratio4.34

Earnings

Next Earnings

Jul 29, 2026

days

EPS (TTM)

$9.17

P/E (TTM)

22.5

Fwd P/E

12.5

SEC Filings & Reported Financials

Earnings History

SEC EDGAR · official filings

SEC filings

SEC Filings

Official EDGAR documents

All filings

Insider Transactions

SEC Form 4 · officers, directors & 10% owners

Dividends & Income

Dividends

This stock does not pay dividends.

Tools & Simulators

If You Had Invested…

Hypothetical return based on historical prices

Investment Amount

* Dividend reinvestment calculated at ex-date price. For informational purposes only.

Discussion

Loading…

Discover

Related Assets

Healthcare

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Drug Manufacturers - General

Location

Cambridge, United States

Employees

7,500

www.biogen.com

Listed on NasdaqGS

iOS App

Get Stock Market ROI on your iPhone

Real-time prices, portfolio tracking, price alerts and AI insights — free on the App Store.

BIIB — Frequently Asked Questions

Is Biogen Inc. (BIIB) a good stock to buy in 2026?

Biogen Inc. (BIIB) shows risks such as high leverage (debt/equity of 35.2). Whether BIIB is a good buy in 2026 depends on your time horizon and risk tolerance — review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.

What is BIIB's stock price today?

Biogen Inc. (BIIB) trades at $205.99, down 1.40% on the session. Prices on this page update throughout the trading day.

Does BIIB pay a dividend?

No. Biogen Inc. (BIIB) does not currently pay a dividend, so the return comes entirely from share-price appreciation.

Is BIIB overvalued?

With a P/E ratio of 22.5×, BIIB trades at a roughly market-average valuation for the healthcare sector. Its PEG ratio is 4.34. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.

What is BIIB's market cap?

Biogen Inc. (BIIB) has a market capitalization of $30.41 billion, classifying it as a large-cap stock in the Healthcare sector.

Disclaimer: This page — including any buy/hold/avoid view, fair value or price estimate — is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.